In some cancers, EGR1 is associated with tumor progression, for instance in prostate and gastric cancer, which possess endocrine components [6, 7], whereas in others, EGR1 exhibits prominent tumor-suppressive activity by activating major tumor suppressor factors, including transforming growth factor-β1, p53, p73, fibronectin, and PTEN. This evidence concerns the gene PTEN and neoplasm.